Perioperative radiotherapy with SOX chemotherapy plus apatinib and camrelizumab for esophagogastric cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2, single-center trial at Ruijin Hospital enrolls adults with previously untreated, localized (T3-4N+M0) gastric or gastroesophageal junction adenocarcinoma who are planned for surgery. Participants receive neoadjuvant radiotherapy combined with SOX chemotherapy plus apatinib (a VEGFR2 inhibitor) and camrelizumab (an anti–PD-1 antibody), followed by surgery and adjuvant courses of the same combination. The trial monitors safety, tolerability, and tumor response to see if the perioperative regimen increases rates of successful resection and reduces recurrence. Key eligibility includes ECOG 0–1 and adequate organ function, while patients with uncontrolled hypertension or bleeding disorders are excluded.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Has previously untreated localized gastric or GEJ adenocarcinoma as defined by T3-4N+M0;
* Plans to proceed to surgery following pre-operative chemotherapy. Has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.
* Has adequate organ function.
* Male participants of childbearing potential must agree to use an adequate method of contraception for the course of the study through 120 days after the last dose of therapy.
* Female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of therapy.
* Has life expectancy of greater than 12 months.

Exclusion Criteria:

* Uncontrolled hypertension ( systolic ≥140 mmHg or diastolic ≥90 mmHg despite antihypertensive therapy)
* Known hypersensitivity to any of the study drugs or excipients.
* Known hereditary or acquired bleeding and thrombotic tendencies (e.g. hemophiliacs, coagulation disorders, thrombocytopenia, etc.);
* Congenital or acquired immune deficiency (e.g. HIV infected)

Where it's running

• Ruijin Hospital, Shanghai Jiaotong University School of Medicine
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Shu-Bei Wang, MD
• Email: wangshubei@163.com
• Phone: +86-021-64370045

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• VRT106 plus camrelizumab and apatinib for advanced HCC in patients who have tried prior ICIs

  This study tests VRT106, with camrelizumab and apatinib, to see if it helps people with advanced hepatocellular carcinoma who have already had prior immune checkpoint inhibitors fail.

  Recruiting Phase 2/3 Guangzhou Virotech Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT07589244

• Y-90 microspheres with camrelizumab and/or apatinib versus Y-90 alone or cTACE for unresectable liver cancer

  This trial will test whether adding camrelizumab and/or apatinib to Y-90 microsphere treatment helps people with unresectable, non-metastatic hepatocellular carcinoma more than Y-90 alone or conventional TACE.

  Recruiting at 2 sites Phase 2 GrandPharma (China) Co., Ltd. · Beijing and 2 other locations · NCT07334483

• Camrelizumab plus apatinib with or without FOLFOX chemotherapy for advanced liver cancer

  This research will test whether adding FOLFOX chemotherapy to camrelizumab plus apatinib helps adults with advanced hepatocellular carcinoma who have not received prior systemic treatment.

  Recruiting Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07267806

• Apatinib and camrelizumab plus TACE before liver resection for centrally-located BCLC‑B hepatocellular carcinoma

  This trial tests whether giving apatinib and camrelizumab together with TACE before planned liver surgery can shrink tumors and improve outcomes for adults with centrally-located BCLC stage B hepatocellular carcinoma who are eligible for resection.

  Recruiting Phase 2 Tongji Hospital · Wuhan, Hubei · NCT07154082

• Camrelizumab plus apatinib and eribulin versus physician's choice chemotherapy for advanced triple-negative breast cancer

  This trial tests whether combining camrelizumab, apatinib, and eribulin works better than your doctor's chosen chemotherapy for adults with advanced triple-negative breast cancer who have had 1–4 prior systemic treatments.

  Recruiting at 5 sites Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong and 6 other locations · NCT06889688

• Combination therapy for advanced liver cancer patients

  This study is testing a new combination treatment for patients with advanced liver cancer to see if it can improve their chances of survival and how well they tolerate it.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT06607107

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.